share_log
Benzinga ·  Jul 10 07:41
Kazia Therapeutics Announces Phase Ii/Iii Clinical Trial Results For Paxalisib In Glioblastoma; Company Says GBM AGILE Trial Data Shows Clinical Improvement In Prespecified Secondary Analysis
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment